Working… Menu

Pilot Study of NanoKnife for Ablation of Prostate Cancer in Low Risk Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01972867
Recruitment Status : Withdrawn
First Posted : October 31, 2013
Last Update Posted : February 11, 2016
Information provided by (Responsible Party):
Angiodynamics, Inc.

Brief Summary:
The purpose of this study is to evaluate the feasibility and short-term safety and effectiveness of the NanoKnife™ System when used to ablate localized prostate cancer in low risk subjects with organ-confined prostate cancer and a low risk of recurrence. This study will evaluate the feasibility of the NanoKnife™ System as a focal therapy.

Condition or disease Intervention/treatment Phase
Prostate Cancer Device: NanoKnife Procedure Not Applicable

Detailed Description:

This study is designed to be a prospective, non-randomized pilot study in 6 subjects treated at up to three (3) clinical sites. This study will involve six (6) subjects who meet the low risk prostate cancer criteria defined by this protocol. The subjects' prostate cancer foci, the location of which will be determined by ultrasound guided transperineal 3-Dimensional Prostate Mapping Biopsy (3D-PMB), will be targeted for treatment with the NanoKnife System. The primary objective of this portion of the study will be to evaluate procedural and short-term post treatment safety of the NanoKnife treatment via incidence of adverse events and evaluation of effect on urologic (urinary and erectile) function. The secondary objective of this study is to evaluate the short term efficacy of the NanoKnife treatment. Local efficacy in the area of treatment will be assessed via histological evaluation of 3D-PMB cores obtained throughout the half of the prostate where treatment was targeted at three (3) months post NanoKnife treatment, to evaluate the ablation zone created by the NanoKnife treatment. Following the 3 month biopsy assessment the data from these 6 subjects will be submitted to FDA for confirmation of short term safety and efficacy.

This group of subjects will continue to be followed for safety and efficacy for 2 years. Safety will be assessed via incidence of adverse events and evaluation of effect on urologic function and quality of life. Local efficacy will be characterized via MR imaging and evaluated via post treatment prostate-specific antigen (PSA) kinetics including time to PSA nadir and post-nadir PSA stability.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study in Human Subjects Evaluating the Use of the NanoKnife System for Ablation of Prostate Cancer Tissue in a Low Risk Patient Population
Study Start Date : November 2013
Estimated Primary Completion Date : August 2016
Estimated Study Completion Date : August 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: NanoKnife Procedure
The NanoKnife procedure will be performed on focal prostate tumors, under ultrasound guidance.
Device: NanoKnife Procedure
Under general anesthesia and with paralytic on board, patients will have monopolar probes inserted bracketing the tumor. A total of 90 electrical pulses will be delivered to irreversibly electroporate the tissue.
Other Name: NanoKnife (Model HVP01)

Primary Outcome Measures :
  1. Safety [ Time Frame: 3 months post procedure ]

    To determine safety by evaluating AE incidence, type, duration, severity and relationship to study device.

    Determine morbidity profile by evaluating urinary and erectile function

Secondary Outcome Measures :
  1. Procedural Effects [ Time Frame: 2 Years ]

    Secondary Objectives

    • To determine completeness of ablation in the targeted prostate cancer tissue as 3D-PMB at 3 months post-treatment
    • Determine post-treatment PSA kinetics
    • Determine effectiveness of therapy by post-treatment imaging (necrosis, presence of residual tissue)
    • Determine effectiveness of therapy by rates of biochemical and clinical progression; need for secondary or adjuvant treatment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Ages 50-70 years,
  2. Have histologically confirmed organ-confined prostate cancer - Clinical Stage T1 or T2a,
  3. Have a PSA less than 10 ng/mL,
  4. Have a PSA density less than 0.15 ng/ml/cc,
  5. Have a PSA velocity less than 2 ng/ml yearly in the year prior to diagnosis,
  6. Has no Gleason grade 4 or 5,
  7. Has a single lesion with a maximum size of ≤ 12 mm with ≤ 10 mm of capsular contact as confirmed by MR imaging,
  8. Has ≤20% of cancer in any biopsy core,
  9. Has ≤ 7 mm of cancer in any biopsy core,
  10. Has ≤ 33% positive biopsy cores
  11. No evidence of extraprostatic extension or seminal vesicle invasion by MRI,
  12. Able to visualize prostate gland adequately on transrectal ultrasound imaging during enrollment evaluation,
  13. Has no prostate calcification greater than 5 mm in the treatment zone, as noted by TRUS,
  14. Has the ability to stop anticoagulant and anti-platelet therapy for seven days prior to and seven days post procedure,
  15. Must sign a written informed consent,
  16. Understands and accepts the obligation and is logistically able to present for all scheduled follow-up visits.

Exclusion Criteria:

  1. Have known hypersensitivity to pancuronium bromide, atracurium or cisatracurium,
  2. Have known hypersensitivity to ciprofloxacin or any member of the quinolone class of antimicrobial agents,
  3. Have anesthesia surgical assignment category IV or greater,
  4. Have a bleeding disorder as determined by prothrombin time (PT) > 14.5 seconds, partial thromboplastin time (PTT) > 34 seconds, and platelet count < 140,000 platelets per microliter of circulating blood1
  5. Have an active urinary tract infection (UTI),
  6. Have a history of bladder neck contracture,
  7. Are interested in future fertility,
  8. Have a history (within 3 years) of inflammatory bowel disease,
  9. Have a concurrent major debilitating illness,
  10. Had a malignancy, other than prostate or skin cancer (except malignant melanoma), within 5 years,
  11. Have any active implanted electronic device (e.g., pacemaker),
  12. Are unable to catheterize due to a urethral stricture disease,
  13. Have had prior or current prostate cancer therapies:

    1. Biologic therapy for prostate cancer
    2. Chemotherapy for prostate cancer
    3. Hormonal therapy for prostate cancer within three months of procedure,
    4. Radiotherapy for prostate cancer,
  14. Have had prior transurethral prostatectomy (TURP), or urethral stent,
  15. Have had prior major rectal surgery (except hemorrhoids).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01972867

Layout table for location information
United States, North Carolina
Duke University
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Angiodynamics, Inc.

Layout table for additonal information
Responsible Party: Angiodynamics, Inc. Identifier: NCT01972867     History of Changes
Other Study ID Numbers: ON-NK310
First Posted: October 31, 2013    Key Record Dates
Last Update Posted: February 11, 2016
Last Verified: February 2016
Keywords provided by Angiodynamics, Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases